18 October 2017
News and Views
Links and Services
Extent of early clinical response to infliximab predicts long-term treatment success in active ulcerative colitis, reports this month's Inflammatory Bowel Diseases.
The long-term effectiveness of infliximab in ulcerative colitis (UC) and predictors of treatment
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors